GENERAL POPULATION
Who should be screened?*
1. General screening is recommended at 3 year intervals only for those patient populations known to be at high risk. High risk includes one or more of the following: ≥45 years of age, has a sibling or parent with diabetes; overweight (BMI ≥ 25 kg/m²); are members of a high-risk ethnic population; have delivered a baby weighing >9 lbs. or previously diagnosed with GDM; are hypertensive ≥140/90 mm Hg in adults); have an HDL cholesterol level ≤35 mg/dL and/or a triglyceride level ≥250 mg/dL; polycystic ovary disease; history of vascular disease; habitual physical inactivity.
2. Patient screening is recommended yearly for previous impaired glucose tolerance (IGT)**; previous impaired fasting glucose (IFG)**; overweight people with one or more other risk factors.
3. At increased risk for future diabetes are patients with HgbA1C of 5.7 to 6.4%.

Screening Procedure (Capillary vs. Venous Blood):
Testing of blood with a blood glucose monitoring device intended for home use is not considered a diagnostic procedure. A whole blood screening test must be confirmed two more times using plasma from a venous sample.

1. Fasting Plasma Glucose (FPG) ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no consumption of food or beverage other than water for at least 8 hours. OR
2. 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT). [This measure (OGTT) is not recommended for routine clinical use.] The test requires the use of a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. OR
3. HgbA1C ≥6.5 %. OR
4. Symptoms of diabetes plus casual (random) plasma glucose concentration ≥200 mg/dL (11.1 mmol/L). Casual (random) is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.

In the absence of unequivocal hyperglycemia with symptoms, these criteria must be confirmed by repeat testing (preferably the FPG) on a subsequent day.

Yes
Confirmed Diabetes
Further monitoring of patient with HgbA1C***.

No
No further action

* Exclude those who have no high risk indicators.
** Non-diabetic individuals with an FPG ≥100 mg/dL (5.6 mmol/L) but <126 mg/dL (7.0 mmol/L) are considered to have impaired fasting glucose (IFG), and those with 2-h values in the OGTT ≥140 mg/dL (7.8 mmol/L) but < 200 mg/dL (11.1 mmol/L) are defined as having impaired glucose tolerance (IGT). Both IFG and IGT are risk factors for future diabetes.
*** The method of testing should be one certified by the National Glycohemoglobin Standardization Program (NGSP).

REFERENCES:

PUB #681-NonDOH (January 2013)
GESTATIONAL DIABETES MELLITUS

Who should be screened?
- Risk assessment for Gestational Diabetes Mellitus (GDM) should be undertaken at the first prenatal visit.
- Women with clinical characteristics consistent with a high risk of GDM (marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) should undergo glucose testing as soon as feasible. If they are not found to have GDM at that initial screening, they should be retested between 24 and 28 weeks of gestation.
- Women of average risk should be tested at 24 - 28 weeks gestation.
- Women of low risk status require no glucose testing, but this category is limited to those women meeting all of the following: <25 years of age, normal weight before pregnancy, member of an ethnic group with a low prevalence of GDM, no sibling or parent known to have diabetes, no history of abnormal glucose tolerance and no history of poor obstetric outcome.

SCREENING FOR GESTATIONAL DIABETES MELLITUS

A fasting plasma glucose level > 126 mg/dL (7.0mmol/L) or a casual (random) plasma glucose level > 200 mg/dL (11.1 mmol/L) that are confirmed on a subsequent day meet the threshold for the diagnosis of diabetes and precludes the need for any glucose challenge.

One -Step Approach:
Perform a diagnostic oral glucose tolerance test (OGTT) without prior plasma or serum glucose screening. This approach may be cost-effective in high-risk patients or populations. Use either the 75 gram or 100 gram OGTT described below.

Two -Step Approach:
Perform an initial screening by measuring the plasma or serum glucose concentration 1 hour after a 50 gram oral glucose load. Those who exceed the glucose threshold value of >140 mg/dl (7.8 mmol/l) identify approximately 80% of women with GDM. Those who exceed the glucose threshold value of >130 mg/dl (7.2 mmol/l) identify approximately 90% of women with GDM. Perform either the 75 gram or 100 gram OGTT on those who fail the initial screening.

100-gram Oral Glucose Load OGTT (modified criteria)

<table>
<thead>
<tr>
<th>Sample</th>
<th>mg/dL</th>
<th>mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>95</td>
<td>5.3</td>
</tr>
<tr>
<td>1-hr</td>
<td>180</td>
<td>10.0</td>
</tr>
<tr>
<td>2-hr</td>
<td>155</td>
<td>8.6</td>
</tr>
<tr>
<td>3-hr</td>
<td>140</td>
<td>7.8</td>
</tr>
</tbody>
</table>

Two or more of the venous plasma results must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8 - 14 hours and after at least 3 days of unrestricted diet (<150 gms carbohydrates per day) and unlimited physical activity. The subject should remain seated and should not smoke throughout the test.

75-gram Oral Glucose Load OGTT

<table>
<thead>
<tr>
<th>Sample</th>
<th>mg/dL</th>
<th>mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>95</td>
<td>5.3</td>
</tr>
<tr>
<td>1-hr</td>
<td>180</td>
<td>10.0</td>
</tr>
<tr>
<td>2-hr</td>
<td>155</td>
<td>8.6</td>
</tr>
</tbody>
</table>

Two or more of the venous plasma concentrations must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8 - 14 hours and after at least 3 days of unrestricted diet (>150 gms carbohydrates per day) and unlimited physical activity. The subject should remain seated and should not smoke throughout the test. (This test is not as well validated as the 100gm OGTT.)

PUB #681-NonDOH